北京若生智能科技有限公司
Drug Database
RA

ranibizumab (RTPR 024 / RTPR024 / RanizuRel)

✓ Approved

Reliance Life Sciences Private Limited · VEGFA · 单克隆抗体

什么是 ranibizumab？

ranibizumab 是一种单克隆抗体，由Reliance Life Sciences Private Limited研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intraocular Injection。

药物档案

商品名RTPR 024, RTPR024, RanizuRel
公司Reliance Life Sciences Private Limited
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intraocular Injection
状态Approved
来源： ClinicalTrials.gov, Reliance Life Sciences Private Limited

作用机制

分子靶点

ranibizumab 作用于 1 个分子靶点：

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

ranibizumab 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersNeovascular age-related macular degeneration✓ Approved

相关研究文献

PubMedClinical & experimental optometry2026-10-25

Development full-thickness macular hole and exudative retinal detachment in central retinal vein occlusion after intravitreal ranibizumab.

Yang Yi Y

Intravitreal injection of anti‑vascular endothelial growth factor (VEGF) has become a first-line treatment for macular oedema secondary to central retinal vein occlusion (CRVO). However, there have been recent reports of a surprising complication associated with intravitreal injection of anti-VEGF. We report a case of full-thickness macular hole (FTMH) and exudative retinal detachment (ERD) after intravitreal injection of ranibizumab for macular oedema. A 21-year-old patient with macular oedema secondary to CRVO developed FTMH and ERD in her left eye after the first intravitreal injection of ranibizumab. A 25 G vitrectomy was performed, during which the internal limiting membrane was peeled off followed by filling with silicone oil tamponade. One week after the operation, optical coherence tomography showed closure of the macular hole. Although vitrectomy combined with removal of the inner limiting membrane can reclose macular hole caused by intravitreal injection of anti-VEGF drugs, these cases of FTMH differ from those of idiopathic FTMH in having a poorer visual prognosis. Ophthalmologists should be vigilant in monitoring the possibility of inducing macular hole through treatment with ranibizumab. In addition, ERD associated with CRVO represents a serious vision-threatening complication that merits close clinical attention from ophthalmologists.

PMID 42927738
阅读全文 →
PubMedReports (MDPI)2026-10-25

Spontaneous Resolution of a Unilateral Epiretinal Membrane in Bilateral Peripheral Retinal Vasculopathy: A Case Report.

Avitabile Alessandro A, Ruggeri Maria Ludovica ML, Quarta Alberto A, de Santis Ciacci Corina Valentina CV et al.

Background and Clinical Significance: Epiretinal membranes (ERMs) are uncommon in young patients, and spontaneous anatomical resolution is rare. We report spontaneous disappearance of a unilateral ERM after marked worsening in an 18-year-old woman with bilateral peripheral occlusive/telangiectatic retinal vasculopathy and vitritis of undetermined etiology. Case Presentation: She presented with right-eye (RE) metamorphopsia and uncorrected visual acuity of 20/25. Optical coherence tomography (OCT) showed a macular ERM; fluorescein angiography showed bilateral peripheral telangiectasia, leakage, vascular truncation, and capillary nonperfusion. Bilateral vitritis was present. Treatment comprised a single intravitreal ranibizumab injection in the RE and peripheral laser photocoagulation in both eyes for the vascular abnormalities; the ERM was managed conservatively. Before its disappearance, the ERM showed marked anatomical worsening accompanied by progressive visual decline. RE central macular thickness (CMT) peaked at 901 µm on Day 71; the lowest uncorrected visual acuity, 20/200, was recorded on Days 166 and 187. Posterior vitreous detachment was not clinically detectable throughout follow-up. On Day 243, the ERM was first documented as absent clinically and on OCT; visual acuity with correction was 20/30, CMT was 464 µm, and vitritis was no longer clinically detectable. At approximately 38 months, macular contour remained restored and recorded visual acuity was 20/20 in both eyes. When mapped to the MANE Select transcript, the retained VCAN variant notation corresponds to NM_004385.5:c.2234A>C (p.Lys745Thr); ClinVar reports conflicting classifications, and the finding was therefore considered non-diagnostic. Conclusions: This case documents spontaneous ERM disappearance without vitreoretinal surgery after marked anatomical and functional worsening. The separation mechanism and any causal contribution of ranibizumab or laser photocoagulation remain uncertain.

PMID 42924810
阅读全文 →
PubMedProgress in retinal and eye research2026-10-20

Mastering the Eye: Clinical Paradigm Shifts from Optical Restoration to Genomic Correction.

Zhang Xiulan X, Li Fei F, Huang David D, Yu-Wai-Man Patrick P et al.

Historically, the main operation for cataract was couching, and the interior of the living eye could not be examined until Hermann von Helmholtz introduced the ophthalmoscope in 1851. Since the mid-twentieth century, seven advances have reshaped ophthalmic care. Harold Ridley implanted the first intraocular lens in 1949, and the ophthalmologist Charles Kelman and the engineer Anton Banko developed phacoemulsification, reported in 1967. Robert Machemer performed the first pars plana vitrectomy in 1970, while David Huang and colleagues described optical coherence tomography in 1991. Endothelial keratoplasty, developed by Gerrit Melles and others between 1998 and 2006, replaced only the failing corneal endothelium instead of the full thickness of the cornea. Anti-VEGF therapy followed the purification of VEGF by Napoleone Ferrara and colleagues in 1989 and the approval of ranibizumab in 2006. Minimally invasive glaucoma surgery has spread since 2012, and in 2017 voretigene neparvovec became the first approved gene therapy for an inherited retinal disease. Five of these advances enabled a new type of intervention, whereas endothelial keratoplasty and minimally invasive glaucoma surgery made existing operations safer. For each advance we summarize the best available evidence of benefit to patients and its certainty, which is high for some, such as anti-VEGF therapy, and low for others, such as the effect of imaging on patient outcomes. Each advance created new burdens, from chronic injections to dependence on donor tissue, and routine adoption depended on manufacturing, regulation, cost, reimbursement, and health-system capacity.

PMID 42901316
阅读全文 →
PubMedEuropean journal of ophthalmology2026-10-19

Visual and anatomical outcomes of early versus delayed anti-VEGF switching after bevacizumab loading in diabetic macular oedema.

Ucgul Rukiye Kilic RK, Tekin Kemal K, Temel Dogukan D, Karagoz Furkan F et al.

PurposeTo compare 24-month visual and anatomical outcomes associated with early versus delayed switching from bevacizumab in treatment-naive eyes with center-involving diabetic macular edema (DME) and suboptimal early response.MethodsThis retrospective cohort included 87 eyes with inadequate response (<5 ETDRS-letter gain and/or <20% central macular thickness [CMT] reduction) after three monthly bevacizumab injections. In a month-3 landmark analysis, eyes were classified by the month-3 treatment decision as immediate switch (n = 37) or continued bevacizumab with later switching (n = 50). An observed-timing comparison excluded eyes switched at months 4-5 (n = 7) and compared early switch (month 3; n = 37) with delayed switch (month ≥6; n = 43) to aflibercept 2 mg or ranibizumab. Outcomes from the month-3 decision point were evaluated using adjusted mixed-effects models with categorical time.ResultsAt month 3, BCVA (0.42 versus 0.45 logMAR) and CMT (437 versus 408 µm) were similar in the early- and delayed-switch groups. In the landmark analysis, adjusted 24-month differences were -0.07 logMAR (95% CI, -0.17 to 0.03; P = 0.171), equivalent to 3.5 ETDRS letters favoring immediate switching (95% CI, -1.5 to 8.5), and -36 µm (95% CI, -71 to -1; P = 0.044). In the observed-timing comparison, they were -0.08 logMAR (4.0 letters; 95% CI, -1.5 to 9.5; P = 0.154) and -39 µm (95% CI, -77 to -1; P = 0.044). A ≥ 20% CMT reduction at month 24 occurred in 62.2% versus 37.2%. Total injections numbered 11.2 ± 2.4 versus 14.5 ± 2.6.ConclusionsEarlier switching was associated with greater anatomical improvement in both analyses. A 24-month visual advantage was not demonstrated, although a clinically meaningful benefit could not be excluded.

PMID 42895767
阅读全文 →
PubMedInvestigative ophthalmology & visual science2026-10-16

Individual-Eye Pharmacokinetics of Intravitreal Ranibizumab: Linking Ocular Geometry to Drug Retention Using MRI and Modeling.

Lamirande Patricia P, Gaffney Eamonn A EA, Gertz Michael M, Künnecke Basil B et al.

The purpose of this study was to quantify the influence of ocular geometry on intravitreal (IVT) ranibizumab pharmacokinetics (PKs) in rabbits by integrating magnetic resonance imaging (MRI)-derived geometries, diffusion-based modeling, and PK measurements. MRI was performed to obtain detailed ocular geometries in 39 New Zealand White (NZW) rabbits. Ranibizumab PKs were assessed in the same animals by serial aqueous humour (AH) sampling following single or three 0.5 mg doses. Individual eye parameters were estimated using profile likelihood analysis. A mean first passage time model was developed to predict ocular half-life as a function of eye size and injection location. Simplified ocular models parameterized by axial length (AL) were constructed to assess whether reduced anatomic representations capture population-level trends. MRI-derived vitreous geometries enabled quantification of inter-eye anatomic variability. The study cohort of adult rabbits exhibited a limited range of AL and vitreous volume compared to human variability. Modeling predicted increased ocular half-life with eye size, a trend reproduced by simplified AL-based models. Experimentally estimated half-lives ranged between 2.8 and 4.9 days and showed weak correlation to AL and vitreous volume. The population mean half-life was 3.67 days, consistent with previous results. This study provides a quantitative framework for analyzing IVT PKs at the level of individual eyes. Modeling predicts that ocular geometry influences drug elimination, and this relationship was also detected experimentally in rabbits, albeit over a limited anatomic range. Greater variability in human eye size may therefore contribute to interindividual PK differences and warrants further investigation, as it may inform personalized dosing strategies.

PMID 42885992
阅读全文 →
PubMedBMJ open ophthalmology2026-10-15

Non-inferiority study of the efficacy of ranibizumab BS compared with aflibercept in patients with macular oedema due to untreated branch retinal vein occlusion: REMEDY-BRVO study - study protocol.

Toride Ai A, Ashikaga Kenta K, Yamamoto Shutaro S, Nakagawa Takanori T et al.

PMID 42880818
阅读全文 →

注册免费账户还可查看另外 5674 篇文献

免费注册查看全部文献 →

了解更多ranibizumab